glp 1 receptor agonists effects on cardiovascular risk reduction Results of outcomes trials comparing GLP-1 Complementary Yet Distinct Roles of
Description
doi: 10.1530/JOE-17-0278 66 TufailESanyalSMithalASanyalSChattopadhyayN
Neurology 96 , e2920e2932 (2021)
Because stopping GLP-1 therapy can minimize the long-term health gains
Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats
Objective To investigate whether the use of GLP-1 RAs in patients with T2D is associated with the development of DR, NAION, or DR complications
